ESSA Pharma Inc.

NasdaqCM:EPIX Stock Report

Market Cap: US$9.5m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

ESSA Pharma Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

David Parkinson

Chief executive officer

US$4.1m

Total compensation

CEO salary percentage14.83%
CEO tenure9.8yrs
CEO ownership0.1%
Management average tenureno data
Board average tenure8yrs

Recent management updates

Recent updates

Companies Like ESSA Pharma (NASDAQ:EPIX) Are In A Position To Invest In Growth

Aug 21
Companies Like ESSA Pharma (NASDAQ:EPIX) Are In A Position To Invest In Growth

We're Not Very Worried About ESSA Pharma's (NASDAQ:EPIX) Cash Burn Rate

Feb 18
We're Not Very Worried About ESSA Pharma's (NASDAQ:EPIX) Cash Burn Rate

ESSA Pharma (NASDAQ:EPIX) Is In A Good Position To Deliver On Growth Plans

Aug 16
ESSA Pharma (NASDAQ:EPIX) Is In A Good Position To Deliver On Growth Plans

Estimating The Fair Value Of ESSA Pharma Inc. (NASDAQ:EPIX)

Jan 25
Estimating The Fair Value Of ESSA Pharma Inc. (NASDAQ:EPIX)

We're Hopeful That ESSA Pharma (NASDAQ:EPIX) Will Use Its Cash Wisely

Dec 15
We're Hopeful That ESSA Pharma (NASDAQ:EPIX) Will Use Its Cash Wisely

CEO Compensation Analysis

How has David Parkinson's remuneration changed compared to ESSA Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2025n/an/a

-US$25m

Mar 31 2025n/an/a

-US$28m

Dec 31 2024n/an/a

-US$31m

Sep 30 2024US$4mUS$602k

-US$29m

Jun 30 2024n/an/a

-US$28m

Mar 31 2024n/an/a

-US$28m

Dec 31 2023n/an/a

-US$26m

Sep 30 2023US$814kUS$578k

-US$27m

Jun 30 2023n/an/a

-US$27m

Mar 31 2023n/an/a

-US$29m

Dec 31 2022n/an/a

-US$33m

Sep 30 2022US$922kUS$549k

-US$35m

Jun 30 2022n/an/a

-US$37m

Mar 31 2022n/an/a

-US$37m

Dec 31 2021n/an/a

-US$39m

Sep 30 2021US$2mUS$518k

-US$37m

Jun 30 2021n/an/a

-US$33m

Mar 31 2021n/an/a

-US$29m

Dec 31 2020n/an/a

-US$25m

Sep 30 2020US$3mUS$492k

-US$23m

Jun 30 2020n/an/a

-US$22m

Mar 31 2020n/an/a

-US$21m

Dec 31 2019n/an/a

-US$15m

Sep 30 2019US$996kUS$469k

-US$13m

Compensation vs Market: David's total compensation ($USD4.06M) is above average for companies of similar size in the US market ($USD610.00K).

Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.

CEO

David Parkinson (75 yo)

9.8yrs
Tenure
US$4,057,237
Compensation

Dr. David Ross Parkinson, M.D., is Director of Angiocrine Bioscience, Inc. Dr. Parkinson has been a Director of Realm Therapeutics plc. since July 31, 2019. He serves as Member of Advisory Board at AsedaSc...

Board Members

NamePositionTenureCompensationOwnership
David Parkinson
President10.3yrsUS$4.06m0.14%
$ 13.2k
Sanford Zweifach
Independent Director6.3yrsUS$502.39k0%
$ 0
Richard Glickman
Independent Chairman of the Board15yrsUS$707.64k0.11%
$ 10.4k
John Martin
Independent Director6.3yrsUS$492.39k0.030%
$ 2.9k
Franklin Berger
Independent Director10.6yrsUS$504.39k1.66%
$ 157.8k
Scott Requadt
Independent Director9.8yrsUS$501.39k0.063%
$ 6.0k
Marella Thorell
Independent Director6.3yrsUS$502.14k0.0061%
$ 579.7
Marianne Sadar
Scientific Advisor6.3yrsUS$229.20kno data
Raymond Andersen
Scientific Advisorno dataUS$229.20kno data
8.0yrs
Average Tenure
67yo
Average Age

Experienced Board: EPIX's board of directors are considered experienced (8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/10 05:17
End of Day Share Price 2025/10/08 00:00
Earnings2025/06/30
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ESSA Pharma Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Maurice RaycroftJefferies LLC
Soumit RoyJonesTrading Institutional Services, LLC
Elemer PirosRoth Capital Partners